Lynn Onstad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lynn Onstad has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Stephanie J. Lee
Fred Hutchinson Cancer Center, Seattle, WA
25 shared publications - Catherine J. Lee
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
12 shared publications - Ana Triguero
Department of Hematology Hospital Clinic de Barcelona Barcelona Spain
11 shared publications - Carmen Martínez
Hospital Clínic Barcelona
11 shared publications - Clara García-Calderón
Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Junta de Andalucía, Consejo Superior de Investigaciones Científicas), Seville, Spain
11 shared publications - Eduardo Rodríguez-Arbolí
Department of Hematology, Hospital Universitario Virgen del Rocio
11 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 895.e1-895.e8
Fear of Cancer Recurrence in Hematopoietic Cell Transplantation Survivors
- 23 March 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 895.e1-895.e8
Open AccessFear of Cancer Recurrence in Hematopoietic Cell Transplantation Survivors
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
Supplementary Figure from eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
Supplementary Figure from eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the phosphoflow analyses of T-cell activation signaling pathways
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the phosphoflow analyses of T-cell activation signaling pathways
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n=11 R, n=4 NR) (B), unswitched memory B cells cells (C1D1: n=12 R, n=5 NR; C2D1: n=12 R, n=4 NR; C4D1: n=11 R, n=3 NR) (C) and switched memory B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=4 NR) (D). E) Fold change in CD268 (BAFF) expression on B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=3 NR). MFI normalised ratios were used for expression quantification. MFI, median fluorescence intensity; n.s., non-statistically significant.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Fold change from baseline in the absolute count of circulating B cells (C1D1: n=13 responders [R], n=6 non-responders [NR]; C2D1: n=13 R, n=6 NR; C4D1: n=12 R, n=4 NR) (A), naive B cells (C1D1: n=11 R, n=6 NR; C2D1: n=11 R, n=5 NR; C4D1: n=11 R, n=4 NR) (B), unswitched memory B cells cells (C1D1: n=12 R, n=5 NR; C2D1: n=12 R, n=4 NR; C4D1: n=11 R, n=3 NR) (C) and switched memory B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=4 NR) (D). E) Fold change in CD268 (BAFF) expression on B cells (C1D1: n=13 R, n=6 NR; C2D1: n=13 R, n=5 NR; C4D1: n=12 R, n=3 NR). MFI normalised ratios were used for expression quantification. MFI, median fluorescence intensity; n.s., non-statistically significant.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Monoclonal antibodies used in the T-cell co-stimulatory and co-inhibitory molecules expression assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubation with ionomycin (0.91 µg/mL) and PMA (20 µg/mL). Brefeldin A (10 μg/mL) was added in both conditions. Differences between serial evaluations on day 1 of cycles 1, 2 and 4 were examined in skin/joints scGVHD responder (C1D1: n=11; C2D1: n=13; C4D1: n=12) and non-responder patients (C1D1: n=7; C2D1: n=7; C4D1: n=5). n.s., non-statistically significant. *Omnibus Friedman test. In post-hoc tests, only a statistically significant difference between visits C2D1 and C4D1 was detected (p=0.011).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Expression of T-cell co-stimulatory and co-inhibitory molecules. Expression of CTLA-4, TNFRSF18, PD-1, OX40 and 4-IBB in the CD4+ and CD8+ T-cell compartments was measured by flow cytometry under resting conditions and after 4-hour incubation with ionomycin (0.91 µg/mL) and PMA (20 µg/mL). Brefeldin A (10 μg/mL) was added in both conditions. Differences between serial evaluations on day 1 of cycles 1, 2 and 4 were examined in skin/joints scGVHD responder (C1D1: n=11; C2D1: n=13; C4D1: n=12) and non-responder patients (C1D1: n=7; C2D1: n=7; C4D1: n=5). n.s., non-statistically significant. *Omnibus Friedman test. In post-hoc tests, only a statistically significant difference between visits C2D1 and C4D1 was detected (p=0.011).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Representativeness of study participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Representativeness of study participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Baseline absolute counts and relative distributions of key immune cell subpopulations in patients included in the GETH trial and healthy controls
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Baseline absolute counts and relative distributions of key immune cell subpopulations in patients included in the GETH trial and healthy controls